AGI.do

Products

What will AGI do for Avasimibe?

This classification denotes an anti-lipidemic agent with the molecular formula C29H43NO4S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 28LQ20T5RC, chemically known as 2,6-diisopropylphenyl ((2,4,6-triisopropylphenyl)acetyl)sulfamate but generally known as avasimibe, which bears US NIH Compound Identifier 166558. European Medicines Agency schedules Avasimibe in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00632MIG. The term AVASIMIBE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 No. 3, 1999, List 42). Most nations schedule avasimibe under HS 29299000 and SITC 51489. As of Q4 2014, AVASIMIBE remains the US FDA Preferred Term for this commodity. Avasimibe bears US NLM identifiers UMLS ID C0965226 and NCI Concept Code C75252. SMILES: S(=O)(=O)(Oc1c(C(C)C)cccc1C(C)C)NC(=O)Cc1c(C(C)C)cc(cc1C(C)C)C(C)C.

How AGI delivers it

Four ways AGI delivers for Avasimibe

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Avasimibe, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Avasimibe, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Avasimibe connects

measured by

  • Active Ingredient Potencymodel
  • Chiral Enantiomeric Excessmodel
  • Compound Puritymodel
  • Residual Solventmodel

Go deeper

Explore Avasimibe

Read the deeper take on agi.asView as markdown